VMP using weekly and subcutaneous bortezomib is well tolerated and efficacious for newly diagnosed and relapsed myeloma patients

被引：0
|
作者：
O'Sullivan, J. M. [1 ]
Kumar, S. [1 ]
Yeomans, C. [1 ]
Milner, G. [1 ]
Schey, S. [1 ]
Kazmi, M. [1 ]
Streetly, M. J. [1 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
154
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [41] Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma
    Kim, Min Kyoung
    Kim, Kihyun
    Yoon, Dok Hyun
    Suh, Cheolwon
    Lee, Jae Hoon
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Hyo Jung
    Kim, Jin Seok
    Lee, Jeong-Ok
    Eom, Hyeon Seok
    Lee, Won Sik
    Mun, Yeung-Chul
    Do, Young Rok
    Kang, Hye Jin
    BLOOD, 2016, 128 (22)
  • [42] Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma
    Simpson, David
    Liang, James
    Henderson, Ross
    Hanna, Merit
    Merriman, Eileen
    BLOOD, 2012, 120 (21)
  • [43] Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma
    Gut, Natalia
    Yucebay, Filiz
    Dempsey, Jessica
    Li, Junan
    Benson, Don M., Jr.
    BLOOD, 2018, 132
  • [44] Weekly bortezomib with or without glucocorticosteroids is effective in patients with relapsed or refractory multiple myeloma.
    Suvannasankha, A
    Smith, GG
    Abonour, R
    BLOOD, 2005, 106 (11) : 720A - 720A
  • [45] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)
    Mateos, Maria-Victoria
    Dimopoulos, Meletios A.
    Cavo, Michele
    Suzuki, Kenshi
    Jakubowiak, Andrzej J.
    Knop, Stefan
    Doyen, Chantal
    Lucio, Paulo
    Nagy, Zsolt
    Kaplan, Polina
    Pour, Ludek
    Cook, Mark
    Grosicki, Sebastian
    Crepaldi, Andre H.
    Liberati, Anna Marina
    Campbell, Philip
    Shelekhova, Tatiana
    Yoon, Sung-Soo
    Iosava, Genadi
    Fujisaki, Tomoaki
    Garg, Mamta
    Chiu, Christopher
    Wang, Jianping
    Carson, Robin
    Crist, Wendy
    Deraedt, William
    Nguyen, Marie
    Qi, Ming
    San-Miguel, Jesus F.
    BLOOD, 2017, 130
  • [46] Once-Weekly Subcutaneous Bortezomib Plus Oral Cyclophosphamide and Dexamethasone Therapy For Relapsed Or Refractory Multiple Myeloma
    Takamatsu, Yasushi
    Imamura, Yutaka
    Nakazato, Tomonori
    Uike, Naokuni
    Miyashita, Kaname
    Saburi, Yoshio
    Harada, Naoki
    Ota, Shuichi
    Imamura, Rie
    Miyamoto, Toshihiro
    BLOOD, 2013, 122 (21)
  • [47] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)
    Mateos, M., V
    Dimopoulos, M. A.
    Cavo, M.
    Suzuki, K.
    Jakubowiak, A.
    Knop, S.
    Doyen, C.
    Lucio, P.
    Nagy, Z.
    Kaplan, P.
    Pou
    Cook, M.
    Grosicki, S.
    Crepaldi, A.
    Liberati, A. M.
    Campbell, P.
    Shelekhova, T.
    Yoon, S. S.
    Iosava, G.
    Fujisaki, T.
    Garg, M.
    Chiu, C.
    Wang, J.
    Carson, R.
    Crist, W.
    Deraedt, W.
    Nguyen, H.
    Qi, M.
    San-Miguel, J.
    HAEMATOLOGICA, 2018, 103 : 22 - 22
  • [48] Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
    Hoff, Fieke W.
    Banerjee, Rahul
    Khan, Adeel M.
    McCaughan, Georgia
    Wang, Bo
    Wang, Xiaoliang
    Roose, James
    Anderson Jr, Larry D.
    Cowan, Andrew J.
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [49] Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages
    Pawlyn, Charlotte
    Brioli, Annamaria
    Gregory, Walter
    Hinsley, Samantha
    Lindsay, Jindriska
    Cook, Gordon
    Milligan, Donald
    Chapman, Claire
    Owen, Roger G.
    Drayson, Mark T.
    Russell, Nigel
    Jackson, Graham H.
    Davies, Faith E.
    Morgan, Gareth J.
    BLOOD, 2013, 122 (21)
  • [50] Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
    Fieke W. Hoff
    Rahul Banerjee
    Adeel M. Khan
    Georgia McCaughan
    Bo Wang
    Xiaoliang Wang
    James Roose
    Larry D. Anderson
    Andrew J. Cowan
    S. Vincent Rajkumar
    Gurbakhash Kaur
    Blood Cancer Journal, 14
12345